OCULAR THERAPEUTIX, INC (OCUL) › Shareholders' EquityOCULAR THERAPEUTIX, INC (OCUL) — Shareholders' EquityAnnual figures by period end, from SEC filings.2011-12-31: -$32.73M2012-12-31: -$46.61M2013-12-31: -$59.47M2014-12-31: $58.70M2015-12-31: $89.59M2016-12-31: $52.01M2017-12-31: $26.15M2018-12-31: $35.88M2019-12-31: -$3.63M2020-12-31: $76.09M2021-12-31: $88.00M2022-12-31: $35.38M2023-12-31: $91.13M2024-12-31: $315.34M2025-12-31: $654.31M$654.31M2011-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$654.31M+107.5%2026-02-05Balance as of period end2024-12-31$315.34M+246.0%2026-02-05Balance as of period end2023-12-31$91.13M+157.6%2026-02-05Balance as of period end2022-12-31$35.38M-59.8%2026-02-05Balance as of period end2021-12-31$88.00M+15.6%2025-03-03Balance as of period end2020-12-31$76.09M—2024-03-11Balance as of period end2019-12-31-$3.63M-110.1%2023-03-06Balance as of period end2018-12-31$35.88M+37.2%2022-02-28Balance as of period end2017-12-31$26.15M-49.7%2020-03-12Balance as of period end2016-12-31$52.01M-41.9%2020-03-12Balance as of period end2015-12-31$89.59M+52.6%2019-03-07Balance as of period end2014-12-31$58.70M—2018-03-08Balance as of period end2013-12-31-$59.47M—2017-03-10Balance as of period end2012-12-31-$46.61M—2016-03-10Balance as of period end2011-12-31-$32.73M—2015-03-20Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)